TECH as reported
Bio-Techne reported $1.21B of revenue over the trailing twelve months, +0.17% on the year before. 11 reported series are charted on this page, each one as filed.
$1.21B
Revenue, trailing twelve months · to Q3 2026 · +0.17% against the twelve months before
- Net Income
- $110M
Net Income · −17% year on year · trailing twelve months to Q3 2026
- Free Cash Flow
- $270M
Free Cash Flow · +22% year on year · trailing twelve months to Q3 2026
- Op Margin
- 13%
Op Margin · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.21B | +0.17% | Q3 2026 |
| Net Income | $110M | −17% | Q3 2026 |
| EPS | $0.69 | −17% | Q3 2026 |
| Gross Margin | 65% | n/a | Q3 2026 |
| Op Margin | 13% | n/a | Q3 2026 |
| Net Margin | 9.2% | n/a | Q3 2026 |
| ROE | 4.3% | n/a | Q3 2026 |
| ROA | 3.4% | n/a | Q3 2026 |
| ROIC | 4.4% | n/a | Q3 2026 |
| Free Cash Flow | $270M | +22% | Q3 2026 |
| P/E | 105 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Bio-Techne (TECH) - Revenue & ProfitRevenue & ProfitBio-Techne (TECH)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com